Akthelia receives European Commission Seal of Excellence
- Apr 5
Meet Akthelia Pharmaceuticals at the LSX World Congress 2024
- Nov 27, 2023
Dr Sonja Srdanović joins Akthelia Pharma as R&D Program Manager for Inflammation and Infection
- Oct 30, 2023
Meet Akthelia Pharmaceuticals at Nordic Life Science Days, 2023
- Oct 26, 2023
Dr Helga Einarsdóttir joins Akthelia Pharma as R&D Program Manager for Wound Therapeutics
- Apr 17, 2023
Akthelia Pharmaceuticals and the University of Iceland Secure a €6M EU Horizon Grant
- Dec 12, 2022
Akthelia Pharmaceuticals is selected to present at the Science4Peace Summit in Stockholm
- Sep 1, 2022
Akthelia Pharmaceuticals Participates in the LSX Leaders Nordic Congress 2022
- Jun 29, 2022
Akthelia Pharmaceuticals Announces Second Close of Follow-Up Pre-Seed Equity Round
- Jan 20, 2022
Akthelia Pharmaceuticals Announces Close of Follow-Up Pre-Seed Equity Round
- Sep 1, 2021
Dr Steingrímur Stefánsson joins Akthelia Pharma in the role of Senior Scientist
- Jun 1, 2021
Akthelia Pharma is awarded a RANNÍS grant for wound healing
- Sep 1, 2020
Akthelia Pharma Announces Close of a Pre-Seed Equity Round
- Jun 15, 2019
Akthelia Pharma is awarded a RANNÍS grant towards a POC of its innate immunity approach
- Jan 28, 2019
Akthelia will attend the 2019 ANTIMICROBIAL PEPTIDES GORDON RESEARCH CONFERENCE